Revealing sit-downs with executives shaping the future of the global mining industry.
Episodes
Friday Aug 23, 2019
Friday Aug 23, 2019
Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment.
Genprex Inc. (NASDAQ: GNPX) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs to its pipeline this quarter alone as the company continues to diversify and build depth within neuroscience and pursue therapeutic adjacencies. Celgene Corporation (NASDAQ: CELG) announced recently that its stockholders voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (NYSE: BMY). This key milestone brings the two complementary biopharmaceutical companies one step closer to combining their efforts on a shared mission of discovering, developing and delivering innovative medicines for patients with serious diseases.